Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 93 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5287
Sealed predictions
- ALG13 in dopamine neurons, braak+0.05 (p 0.893) → -0.26 (p 0.493)receipt 5295
Swarm cases
receipt 5295: ALG13 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.767, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.942, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.894, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to +0.05, sign flips 1; without severely affected donors -0.08 (p 0.767, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ALG13 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts